How to Interpret a 7-OH Study

Start with the experiment, not the headline

A 7-OH study tells you what happened in a particular experiment, not automatically what will happen to a person using a commercial product. Before accepting a claim that something is "stronger," identify the study type, species, measured endpoint, comparator, and limitations.

This is an educational research-reading guide. It does not provide dosing or treatment advice and has not undergone qualified medical review.

7-OH means 7-hydroxymitragynine. Isolated-compound, botanical-kratom, and concentrated-product studies are not interchangeable. FDA's 2025 assessment identifies formulation and attribution limits. FDA scientific assessment

For the basic distinction between leaf and concentrated products, read What Is 7-OH?. This article is a reading guide, not advice about how much to consume or how to treat withdrawal.

Receptor binding asks about affinity, not the whole effect

Binding experiments ask how a compound interacts with a receptor, a cellular target. Ki is an inhibition constant estimated from a competition-binding experiment. Within comparable conditions, a lower Ki generally indicates higher binding affinity. It does not tell you the largest response the compound can produce, whether it activates the receptor, or how many milligrams a person should take.

Kruegel and colleagues reported a 7-OH Ki of 47 +/- 18 nanomolar at the human mu-opioid receptor, reported as mean +/- standard error. This was a laboratory measurement using expressed receptors, not an experiment in people. Kruegel et al., Table 2

Keep the receptor subtype, units, and experimental conditions attached to a Ki value. "Human receptor" describes the receptor studied; it does not make the experiment a human clinical trial. Do not divide binding values from different papers and present the result as a human potency ratio.

Functional agonism asks what happens after binding

An agonist activates a receptor. Functional tests measure a response, such as cell signaling, rather than binding alone. Two terms help:

• EC50: the concentration producing half the compound's maximum measured response in that assay.
• Emax: the largest measured response, often expressed relative to a reference agonist. Always identify that reference.

Kruegel's G-protein assay found 7-OH to be a partial agonist at the human mu-opioid receptor: EC50 was 34.5 +/- 4.5 nanomolar, reported as mean +/- standard error, and Emax was 47% relative to DAMGO, the reference agonist. "Partial" describes that test, not 47% of a person's risk or a guarantee against overdose. Kruegel et al., Table 1 and Figure 2

FDA describes other functional assays with different maximal responses. Compare pathways and assay conditions before treating those descriptions as contradictory. These measurements alone cannot establish clinical safety. FDA functional-study discussion

The 13-fold figure concerns guinea pig intestinal tissue

Matsumoto and colleagues reported approximately 13-fold greater potency than morphine for inhibiting electrically stimulated contractions in isolated guinea pig ileum, a section of intestine. This was a tissue-response comparison, not a Ki ratio or a human pain trial. Matsumoto et al., 2004, tissue results

FDA repeats that reported comparison with its assay context. It does not turn it into a human dose-equivalence rule. FDA assessment, functional studies

The original paper's printed response values do not reproduce the reported ratio. Its numerical cause remains unresolved; the figure should not be presented as independently verified. Original results, page 2148

You cannot divide a human morphine amount by 13 to obtain a 7-OH amount. A tissue-bath concentration does not establish human absorption, metabolism, brain exposure, breathing effects, or the composition of a retail product. Nor does it mean every 7-OH product is thirteen times as dangerous. The defensible statement keeps the tissue, endpoint, and comparator in the same sentence as the reported number.

Animal outcomes ask different questions again

Animal experiments can measure responses of a whole organism, but the outcome must still be named. Antinociception means reduced response to a noxious stimulus; it is not automatically a person's report of pain relief.

In the 2005 mouse study, repeated 7-OH exposure produced tolerance to the tail-flick antinociceptive effect. Naloxone administration after repeated exposure elicited withdrawal signs. Morphine was a comparison treatment, and vehicle-treated controls were also used. Matsumoto et al., 2005

That result supports concern about physical-dependence potential. It does not supply a human withdrawal timetable, a probability of dependence among consumers, or a clinical diagnosis for an individual. Precipitating withdrawal with an antagonist is also a different experimental question from observing withdrawal after someone stops a product.

When a study reports animal doses in mg/kg, multiplying by a person's body weight is not an established consumer-dose conversion. Species, route, timing, formulation, and endpoint remain part of the result.

Human data are closer to the reader, but design still matters

Not all human evidence answers the same question. A pharmacokinetic study measures exposure over time; a case report describes an individual clinical course. Neither automatically provides a controlled estimate of how often an outcome occurs.

Huestis and colleagues' 2024 randomized, placebo-controlled study measured mitragynine and 7-OH pharmacokinetics after encapsulated dried kratom leaf powder in healthy adults. Participants received botanical material, not isolated 7-OH. Measuring 7-OH in blood after kratom is not the same experiment as administering a concentrated 7-OH product. Huestis et al., 2024

A 2025 report by Sharma and colleagues described one patient with overlapping withdrawal associated with concentrated 7-OH and nicotine pouches, with a substance-use history. It documents a clinical concern, but has no randomized comparator and cannot isolate every contributor or estimate risk across consumers. Sharma et al., case report

The 2026 Lybik case adds a different history: a patient with opioid use disorder reported transitioning from kratom to concentrated 7-OH before presenting with withdrawal after stopping. This abstract describes one clinical course, not a controlled comparison or treatment rule. Lybik et al., abstract

FDA also notes surveillance limitations, including uncertain product identity and difficulty separating 7-OH exposure from mitragynine metabolism. Detection alone does not identify a retail product or prove a single cause of an outcome. These limits do not demonstrate safety; they constrain the conclusions. FDA assessment, epidemiological limitations

Use this original study-reading worksheet

This worksheet is an editorial reading tool, not a validated clinical instrument. Complete it from the original paper, not from a headline. Write "not reported" when necessary.

• Study type: ______. Binding assay, functional cell assay, isolated tissue, animal experiment, human trial, observational study, case report, or assessment? One paper can contain several experiments; make a separate entry for each relevant result.
• Species or population: ______. Name the animal, receptor species and cell system, or human participants. Do not shorten "cells expressing human receptors" to "humans."
• Exposure or formulation: ______. Isolated 7-OH, another alkaloid, leaf, extract, or a retail mixture? Was composition measured or only reported?
• Endpoint: ______. What changed: ligand binding, signaling, contraction, response to heat, blood concentration, symptoms, or another outcome? Was it a planned endpoint or an exploratory observation?
• Comparator: ______. Morphine, DAMGO, mitragynine, placebo, vehicle, baseline, or none? Were conditions comparable? A reference agonist in cells is not a treatment comparison in patients.
• Result and units: ______. Keep Ki, EC50, Emax, concentration, dose, and clinical outcomes separate. Record uncertainty intervals and what the sample size counts: people, animals, or repeated laboratory experiments.
• Limitations: ______. Check sample size, duration, controls, other exposures, missing composition data, reporting bias, funding, and conflicts of interest. A disclosed conflict is context, not automatic disproof.
• Supported conclusion: This study found ______ in ______ compared with ______.
• Unsupported leap: This study does not establish ______. Ask whether the headline changes the species, endpoint, formulation, or certainty.

Worked worksheet: one result from the 2004 paper

• Study type: isolated-tissue functional experiment, not its separate binding or mouse experiments.
• Species: guinea pig ileum.
• Endpoint: inhibition of electrically stimulated contraction.
• Comparator: morphine.
• Limitations: no human participants; no retail-product dose equivalence.

This entry refers to the original paper's tissue results. Matsumoto et al., 2004

The worksheet prevents a common mistake: borrowing the species from one experiment, a number from another, and a safety conclusion neither measured.

Worked worksheet: the 2025 IV rat breathing experiment

This example uses the author abstract, not a full-text methods review. Zuarth Gonzalez et al., abstract

• Study type: whole-animal respiratory experiment; drugs were administered intravenously, not swallowed as retail products.
• Species: awake, freely moving female and male Sprague-Dawley rats.
• Endpoint: breathing frequency, tidal volume (air per breath), and minute volume (air per minute), measured with whole-body plethysmography.
• Comparator: morphine and mitragynine; naloxone was used to test reversal of respiratory effects.
• Finding: 7-OH and morphine reduced these breathing measures; naloxone reversed their respiratory depression. Mitragynine increased breathing frequency, which naloxone did not change.
• Limitations: the abstract does not provide enough detail to appraise allocation, blinding, or every control. Intravenous rat exposure cannot establish human oral-product risk magnitude or a safe amount.

The supported conclusion is a respiratory hazard in this animal experiment, not a consumer conversion or reassurance about another alkaloid. For your worksheet, keep route beside species and endpoint; otherwise a true finding can become a misleading human claim.

What to do when the headline overreaches

Rewrite the claim so it preserves the experiment: "The authors reported a comparison in this tissue assay," or "This case report describes one patient's clinical course." If you cannot locate the endpoint and comparator, leave the claim unresolved rather than upgrading it to a universal rule.

For broader context and evidence limits, read Science and Evidence. For terminology and product distinctions, return to What Is 7-OH?. If the question is about symptoms or difficulty stopping, use Get Help rather than trying to calculate a dose from a paper.